Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−90 JPY
−589.21 M JPY
61.11 M JPY
5.20 M
About CYFUSE BIOMEDICAL K K
Sector
Industry
Headquarters
Minato-ku
Website
Founded
2010
ISIN
JP3311800001
FIGI
BBG01B7D9B40
Cyfuse Biomedical KK develops and manufactures cell regenerative systems. It focuses on developing arteries using patient's skin cells and three-dimensional (3D) printing. The firm's business activities encompass development, manufacturing, and sales of 3D tissue products. It also offers Regenova, a robotic system that facilitates the fabrication of 3D cellular structures by placing cellular spheroids in fine needle arrays according to pre-designed 3D data. The company was founded by Koji Kuchiishi and Koichi Nakayama on August 11, 2010 and is headquartered in Minato-ku, Japan.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 4892 is 545 JPY — it has increased by 7.07% in the past 24 hours. Watch CYFUSE BIOMEDICAL K K stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange CYFUSE BIOMEDICAL K K stocks are traded under the ticker 4892.
4892 stock has risen by 15.47% compared to the previous week, the month change is a −3.20% fall, over the last year CYFUSE BIOMEDICAL K K has showed a −32.21% decrease.
4892 reached its all-time high on Dec 5, 2022 with the price of 2,468 JPY, and its all-time low was 430 JPY and was reached on Nov 20, 2024. View more price dynamics on 4892 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
4892 stock is 18.41% volatile and has beta coefficient of 1.01. Track CYFUSE BIOMEDICAL K K stock price on the chart and check out the list of the most volatile stocks — is CYFUSE BIOMEDICAL K K there?
Today CYFUSE BIOMEDICAL K K has the market capitalization of 4.14 B, it has increased by 0.41% over the last week.
Yes, you can track CYFUSE BIOMEDICAL K K financials in yearly and quarterly reports right on TradingView.
CYFUSE BIOMEDICAL K K is going to release the next earnings report on Feb 12, 2025. Keep track of upcoming events with our Earnings Calendar.
4892 net income for the last quarter is −216.97 M JPY, while the quarter before that showed −222.94 M JPY of net income which accounts for 2.68% change. Track more CYFUSE BIOMEDICAL K K financial stats to get the full picture.
No, 4892 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 3, 2024, the company has 21.00 employees. See our rating of the largest employees — is CYFUSE BIOMEDICAL K K on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CYFUSE BIOMEDICAL K K EBITDA is −805.60 M JPY, and current EBITDA margin is −1.08 K%. See more stats in CYFUSE BIOMEDICAL K K financial statements.
Like other stocks, 4892 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CYFUSE BIOMEDICAL K K stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CYFUSE BIOMEDICAL K K technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CYFUSE BIOMEDICAL K K stock shows the sell signal. See more of CYFUSE BIOMEDICAL K K technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.